Phase IIb trial in 263 participants with mild Alzheimer's disease: ABBV-552 (1, 5 or 15 mg) did not differ from placebo on ADAS-Cog 14 change at week 12 (differences -0.02, -0.42 and 0.25; all non-significant). No safety concerns were identified.
RCTn = 263
Lynch et al. ABBV-552 in patients with mild Alzheimer's disease: a randomized phase IIb trial